

# Annual Report of Communicable Diseases in San Francisco 2014

September 2017

Communicable Disease Control & Prevention  
San Francisco Department of Public Health

**Cora Hoover, MD, MPH**

Director, Communicable Disease Control and Prevention  
San Francisco Department of Public Health

**Tomás J. Aragón, MD, DrPH**

Health Officer, City and County of San Francisco  
Director, Population Health Division  
San Francisco Department of Public Health

**Barbara A. Garcia, MPA**

Director  
San Francisco Department of Public Health



**POPULATION HEALTH DIVISION**  
SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

This annual report summarizes notifiable disease reports received by the Communicable Disease Control Unit (CDCU) of the San Francisco Department of Public Health (SFDPH) during 2014. In addition, six diseases were selected for demographic profiling on the basis of the annual burden and severity of disease, public health impact, and specific interest to community health programs. Readers can access previous reports at <http://www.sfcddcp.org> for historical context of disease incidence in San Francisco. Notifiable disease reports managed by other SFDPH sections are not represented here, i.e., tuberculosis, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) and sexually transmitted diseases (STDs) which are managed, respectively, by Tuberculosis Control, HIV Surveillance and STD Prevention and Control Sections.

---

## Table of Contents

---

|  |    |
|--|----|
| I. <b>Methods and Definitions</b> .....  | 3  |
| II. <b>Notes on 2014 Surveillance Data</b> .....   | 8  |
| III. <b>TABLE 1:</b> Frequency of Reportable Diseases in San Francisco, 2014 .....   | 20 |
| IV. <b>TABLE 2:</b> Frequency and Unadjusted Rates for Six Selected Diseases by Age, San Francisco, 2014 .....             | 21 |
| V. <b>TABLE 3:</b> Frequency and Unadjusted Rates for Six Selected Diseases by Sex, San Francisco, 2014 .....              | 22 |
| VI. <b>TABLE 4:</b> Frequency and Unadjusted Rates for Four Selected Diseases by Race/Ethnicity, San Francisco, 2014 ..... | 23 |
| VII. <b>TABLE 5:</b> San Francisco Population Estimates by Sex, Age and Race/Ethnicity, 2014 .....                         | 24 |
| VIII. <b>Appendices.</b> .....   | 25 |
| a. Notifiable Disease - Historical Changes (2004 - 2014) .....   | 26 |
| b. Definitions for Select Notifiable Diseases. ....  | 27 |

---

## Citation

---

This report is in the public domain and may be reproduced with appropriate citation.

Suggested Citation:

Communicable Disease Control & Prevention. *Annual Report of Communicable Diseases in San Francisco, 2014* [Internet]. San Francisco, California: San Francisco Department of Public Health; September 2017. 27 pp.

Available from: <http://www.sfcddcp.org>



---

## Acknowledgements

---

This report was prepared by Melissa Ongpin, MPH and Sara Ehlers, MPH. Other staff recognized for their crucial efforts include current and former staff of the Communicable Disease Control and Prevention Section and Applied Research, Community Health Epidemiology and Surveillance Branch (Wayne Enanoria, PhD, MPH; Diane Portnoy, MPH; Melissa Sanchez, PhD, MA; Wendy Lu, MPH; Jane Yang, MPH; Yanyuan Liu, MPH; David Stier, MD; Haroon Ahmad, MPH; Anna Branzuela; Robin Buckley; Karen Luk; Jessie Wong, Patricia Zialcita, MS), as well as Mina Mohammadi, MPH, of the Environmental Health Section and staff of the California Emerging Infections Program. A special thanks to all staff across the health department who assisted when surge capacity was needed. Laboratories, clinicians, and providers reported data. Jackvin Ng developed, managed and supported the surveillance data systems.



*San Francisco Department of Public Health at 101 Grove Street (1935)*

Image reproduced with permission of the San Francisco History Center at the San Francisco Public Library.



## Methods and Definitions

---

### Data Collection

This report includes confirmed and probable reports of disease among San Francisco residents reported to SFPDH from January 1, 2014 through December 31, 2014\*. San Francisco health care providers, laboratories and other mandated reporters are required under Title 17, California Code of Regulations (CCR) (§2500, §2505, §2593, §2641-2643, §2800-2812)<sup>1</sup>, to notify the local health authority of the diagnosis, detection or suspicion of certain diseases and conditions. Reports are confidentially received by fax, telephone, postal mail, or secure electronic file transfer. Reports by fax and postal mail are generally submitted using the California Confidential Morbidity Report (CMR) form<sup>2</sup>. Limited case demographic and clinical information is provided on the CMR. Depending on the disease or condition, disease control staff attempt to contact the health care provider, laboratory and/or patient for follow-up and implementation of disease control measures. Clinical and risk factor data are subsequently collected according to departmental and state protocols. Data were managed with locally designed databases.

The chronic hepatitises are managed by the Viral Hepatitis Surveillance Team.

Notifiable diseases managed by other SFPDH sections (HIV Surveillance, Environmental Health, STD Prevention and Control, and Tuberculosis Control) are not presented in this report:

|  |                                     |
|--|-------------------------------------|
| Acquired Immune Deficiency Syndrome (AIDS) | Human Immunodeficiency Virus (HIV)  |
| Chancroid                                  | Lymphogranuloma Venereum (LGV)      |
| <i>Chlamydia trachomatis</i> infections    | Pelvic Inflammatory Disease (PID)   |
| Gonococcal Infections                      | Pesticide-related illness or injury |
| Hepatitis B, chronic                       | Syphilis                            |
| Hepatitis C infection, past or present     | Tuberculosis                        |

\*Disease incidents of confirmed and probable diseases were included in this report for all diseases, except animal rabies (only confirmed cases were reported), campylobacteriosis (confirmed, probable, and suspect cases), salmonellosis (confirmed, probable, and suspect cases), and shigellosis (confirmed, probable, and suspect cases). The laboratory criteria for case definitions for these suspect cases of disease include detection from a clinical specimen using a non-culture based method. See Notes on Surveillance Data for further discussion of culture-independent diagnostic testing.

---

### Population Under Surveillance

CDCU reports cases of CCR Title 17 reportable diseases among residents living in the City and County of San Francisco. Cases of reportable disease reported to CDCU occurring in non-residents are considered “out of jurisdiction,” referred to their respective jurisdictions of residency for follow-up and not included in this report.

San Francisco population estimates were obtained from the California Department of Finance (DOF) Demographic Research Unit<sup>3</sup>; DOF estimates are based on the U.S. Census counts. This report uses DOF projections produced in 2014 for the 2014 San Francisco population; the population count is estimated to be 840,392 (Table 5)<sup>3</sup>.



---

## Racial and Ethnic Categorization

---

People were classified as one of the following: American Indian/Alaska Native, Asian/Pacific Islander, African American (Black), Hispanic, or White. A person with Hispanic ethnicity, regardless of race, was classified as Hispanic, while Non-Hispanics were categorized by their race designation. Occasionally, patients were classified as Other race. Because the category Other is not clearly defined and no reliable San Francisco population estimate exists for it, race-specific rates were not calculated for this population group. Only the frequency values for the race Other were included in the incidence tables.

In 2000, the United States Census Bureau began allowing multiple race designations for its decennial population census; therefore, the California DOF population estimates also include an additional race category, Multiple Race. Because CDCU only collects a single race designation, a bridging method established by the California DOF was used to reallocate the population in the Multiple Race category to single race categories<sup>4</sup>. This method provided reproducible denominators for calculating race-stratified incidence rates.

---

## Demographic Data

---

Depending on the disease, demographic information was usually ascertained through patient interviews, medical chart abstraction or health care provider interviews. Because not all individual cases of disease are investigated by the local health department (e.g., campylobacteriosis), completeness varied by disease.

Age was calculated by subtracting the date of birth from the date of notification to SFDPH, then dividing the difference by 365.25 (the 0.25 accounts for leap years). Numerical values for age were also routinely collected and entered into the database. If either date used in the age formula was missing but a numerical age was recorded, then this age was used in analyses. The frequency of cases with missing or unknown sex or race/ethnicity information is included in the tables.

---

## Notifiable Disease Definitions

---

The diseases required to be reported to public health and disease definitions can change over time. Changes in disease definitions can impact the numbers of cases of disease reported to the SFDPH.

Please see this report's appendices for a list of notifiable disease definition changes from 2004 to 2014 and definitions for select notifiable diseases. Changes in notifiable disease definitions from 1986 to 2003 are documented in The San Francisco Communicable Disease Report 1986-2003 (May 2005), accessible at: <http://sfcdcp.org/publications.html>.

---

## Statistical Calculations

---

SAS version 9.3 (SAS Institute Inc., Cary, NC) was used to calculate crude incidence rates, age-specific rates, three-year moving averages and confidence intervals. For this report, the crude incidence rate (IR) is defined as the number of new cases of disease per 100,000 residents at risk during a given year. The denominator for all diseases, except infant botulism, congenital rubella, influenza deaths for people aged 0-64 years, and invasive *H. influenzae*, was the total San Francisco population. The population at risk for infant botulism and congenital rubella was San Francisco residents less than one year of age, while for the invasive *H. influenzae* rate and influenza death rate for persons aged 0-64 years, it was persons less than 15



years of age and persons 0-64 years of age, respectively. Age-adjusted rates were not calculated. Rates and proportions were generally rounded to one decimal place.

**Formula 1.**

$$IR = \left( \frac{n}{p} \right) \times 100,000$$

where  $n$  = Number of Cases and  $p$  = Population at Risk, and each is identified for a one-year period.

Example: In 2014, there were 175 female cases of campylobacteriosis in San Francisco. The estimated number of female residents in 2014 was 414,163. Accordingly, the incidence among females was:

$$IR_{Campy2014_{Females}} = \left( \frac{175}{414,163} \right) \times 100,000 = 42.3 \text{ cases per } 100,000 \text{ population.}$$

---

## Reliability of Rates

---

With rare diseases or with diseases where the number of cases for a particular population group is very small, a minor change in the number of incident cases can result in a relatively large shift in the corresponding rate. Rates and percentages based on a small number of events may be unreliable and are generally subject to substantial variability over time. Unstable rates should not be statistically compared for differences with the rates for other populations or for San Francisco over time. Rates with a relative standard error (RSE) of 23% or greater were considered unstable and identified by an asterisk in tables of this report<sup>5</sup>. Equivalently, numerators less than 20 result in unreliable rates.

**Formula 2.**

$$RSE = \left( \frac{SE_{rate}}{r} \right) \times 100 = \left( \frac{\frac{r/\sqrt{n}}{r}}{r} \right) \times 100 = \left( \sqrt{\frac{1}{n}} \right) \times 100$$

where  $r$  = Rate and  $SE_{rate}$  = Standard Error of a Rate and  $n$  = Number of Cases

Example: In 2014, there were 405 cases of campylobacteriosis cases reported in San Francisco and one case of acute typhoid fever. Accordingly, the relative standard errors for campylobacteriosis and acute typhoid fever are:

$$RSE_{Campy2014} = \left( \sqrt{\frac{1}{405}} \right) \times 100 = 4.97\%$$

The rate derived from the frequency of campylobacteriosis is considered stable (RSE < 23%).

$$RSE_{TyphoidFever2014} = \left( \sqrt{\frac{1}{1}} \right) \times 100 = 100\%$$

The rate derived from the frequency of acute typhoid fever is not stable and is considered unreliable (RSE > 23%).



---

## Exact Confidence Intervals

---

95% Exact Confidence Intervals (95% CI) for incidence rates were approximated from the gamma distribution, using the GAMINV function in SAS to calculate the Poisson confidence limits<sup>6</sup>. Confidence limits were rounded to one decimal place.

The confidence interval provides a useful means for evaluating the precision of a rate calculation. A rate estimate with a wide confidence interval is less precise than a rate with a narrow confidence interval. Using 2014 giardiasis cases as an example, consider the difference between incidence among residents 1-4 years of age (rate=14.9, 95% CI=4.8-34.7) and those aged 35-44 years (rate=29.2, 95% CI=21.1-39.3). The range of possible values among the older age group is less than the range for children 1-4 years of age. The rate among residents 35-44 years is therefore considered more precise. Rates with very large confidence intervals should be interpreted cautiously. In this report, confidence intervals were not displayed for individual cell counts with zero cases.

---

## Aggregate Rates: Three-year moving averages

---

As stated above, with rare diseases or where the number of cases for a particular population group is very small, a minor change in the number of incident cases can result in a relatively large shift in the rate. One approach to minimizing the effect of large rate shifts and allowing detection of overall trends involves the calculation of moving averages. This approach can be used to compare across populations or to compare across time when the two time periods do not overlap. Calculating three-year moving averages involved summing the numerator and denominator over a three year period and dividing by three.

---

## Rules for Data Suppression

---

If the number of cases for a given time period is small and enough demographic information is given, it may be possible to identify an individual case-patient from tabulated data. Therefore, the total annual incidence was required to be at least 19 cases for information about age, sex, and race/ethnicity data to be included. Of those diseases with an annual incidence of 19 or more cases, six diseases were selected for age, sex, and race/ethnicity stratification for this report. These diseases were selected due to their public health importance and/or volume of reports.

---

## Data Limitations

---

The surveillance data was reported by laboratorians, clinicians and other mandated reporters to the local health authority in compliance with public health laws<sup>1</sup>. Reports may be incomplete and/or important demographic, clinical or risk information may not be available upon active follow-up. Because not all cases of disease were detected by the health care system and not all detected cases were reported to the public health department, the information presented in this report may underestimate the true incidence of disease.

---

## Note to Users of this Report

---

Occasionally, users of this report would like to see incidence rates for specific population parameters (e.g., rate of salmonellosis in children <5 years of age in 2014). Simple calculations can be



accomplished by inserting the desired incidence data provided in the tables of this report and the San Francisco population estimates from TABLE 5 into *Formula 1* above. When such calculations are used for grants or technical papers, the citation of this report must explicitly indicate that SFPDH did not perform the calculation.

Example: A grant writer wishes to know the rate of salmonellosis in San Francisco residents younger than 5 years of age in 2014. From TABLE 2, it is known that 17 cases were <1 year of age and 42 cases were 1-4 years of age. Similarly, the number of San Francisco residents in 2014 can be found in TABLE 5:

|         | <u>Female</u> | <u>Male</u> |
|---------|---------------|-------------|
| <1 yr   | 4,341         | 4,517       |
| 1-4 yrs | 16,473        | 17,155      |

Thus, the total number of cases <5 years of age = (17 + 42) = 59 and

the total population <5 years of age = (4,341 + 16,473 + 4,517 + 17,155) = 42,486 and

the rate of salmonellosis =  $\left(\frac{59}{42,486}\right) \times 100,000 = 138.9$  cases per 100,000 population.






## Notes on 2014 Surveillance Data

The following notes are intended to aid in the interpretation of reported cases of selected diseases.

### AMEBIASIS

Amebiasis, an enteric protozoal infection, is among the most frequently reported diseases in San Francisco. Rates of amebiasis declined overall from 2004 to 2014. In the last 25 years, amebiasis rates were highest in 1986 (67.3 cases per 100,000 residents) and have generally been declining since, with the lowest rate observed in 2014 (6.5 cases per 100,000 residents).

In San Francisco, rates of amebiasis were higher in males than in females for all years for which data was available (1986-2014). For these diseases, the disparity between the rates of disease in males and females has decreased over time. In 2014, the rate of amebiasis in women was 0.2 (N=1; 95% CI: 0.0-1.3) and in men was 12.7 (N=54; 95% CI: 9.5-16.5). This disparity is attributed to transmission of these infections through sexual contact among MSM (men who have sex with men)<sup>7</sup>.




### CAMPYLOBACTERIOSIS

*Campylobacter* infections remained the most frequently reported enteric disease in San Francisco (n=405, rate=48.2 per 100,000 residents, 95% CI: 43.6-53.1), with rates higher than any other California jurisdiction (see Figure 2 for comparison to select CA jurisdictions). Of the 405 cases reported in 2014, 55 (13.6%) were classified as suspect, a much greater number than those from 2010 to 2013. In previous annual reports, only confirmed and probable cases were included. See Culture Independent Diagnostic Tests and Surveillance Case Definitions of this report for more information.



Rates of campylobacteriosis declined from 1990 (n=782, rate=108.1 per 100,000 residents, 95% CI: 100.7-116.0) until 2004 (n=297, rate=37.5 per 100,000 residents, 95% CI: 33.4-42.1). Since 2004, rates have been increasing, with some year to year fluctuations; the rate in 2014 (n=405, rate=48.2 per 100,000 residents, 95% CI: 43.6-53.1) was statistically significantly higher than in 2004 (n=297, rate=37.5 per 100,000 residents, 95% CI: 33.4-42.1).



\*Rates for California, Alameda County, Contra Costa County, and San Mateo County from California Department of Public Health Report, *Yearly Summary Reports of Selected General Communicable Diseases in California*<sup>8,9</sup>.

## CULTURE-INDEPENDENT DIAGNOSTIC TESTS AND SURVEILLANCE CASE DEFINITIONS

Culture-independent diagnostic tests (CIDTs) are diagnostic laboratory tests that do not require the culture or isolation of a microorganism to detect or characterize a pathogen. Examples of CIDTs include polymerase chain reaction (PCR) testing, enzyme immunoassay (EIA) testing, nucleic acid amplification testing (NAAT), etc. Laboratories are rapidly adopting use of CIDTs because they are faster and more automated than traditional culture-based testing, multiple pathogens can be identified with one test, syndromic diseases (e.g., respiratory or enteric) can be assessed by multiplex molecular panels, less technical training to perform tests is required, and costs are potentially lower. Unfortunately, without a culture or isolate, subtyping and genotyping (PFGE, MLVA, WGS) cannot be performed, antimicrobial resistance cannot be determined, and detecting and monitoring trends, clusters and outbreaks is more difficult.



It's unclear how the use of CIDTs has affected healthcare provider or laboratory testing practices and thus surveillance data and their interpretation<sup>10</sup>. Possible effects may include the following:

1. Less expensive, faster testing in a more clinically relevant timeframe may lead to an increase in tests ordered by healthcare providers, meaning more disease is detected.
2. Multiple pathogens tested with one test may mean more co-infections are detected.
3. CIDT syndromic panels may increase detection of additional pathogens since the panels may include pathogens not normally found in routine culture procedures.
4. Without an isolate or culture, reflex testing, subtyping, genotyping and antimicrobial testing cannot be performed, which makes detecting and monitoring trends more difficult.

A case definition is a set of uniform criteria used to define a disease for public health surveillance. Before 2012, the national surveillance disease case definitions for campylobacteriosis, salmonellosis, and shigellosis did not include criteria for CIDTs. In 2012, the laboratory criteria for the national disease case definitions for campylobacteriosis, salmonellosis, and shigellosis were updated to include CIDTs; those cases of disease diagnosed by CIDT without culture confirmation were classified as suspect. Because of the increased use of CIDT in 2014 by laboratories reporting to SFDPH, suspect cases of campylobacteriosis, salmonellosis, and shigellosis were included in the case counts for this report\*.

\*As use of CIDTs has risen, case definitions for these three diseases (in 2015 for campylobacteriosis and 2017 for salmonellosis and shigellosis) were revised and those cases of disease diagnosed by CIDT without culture confirmation are now categorized as probable.

## **EBOLA OUTBREAK IN WEST AFRICA & MONITORING OF TRAVELERS FROM EBOLA-AFFECTED COUNTRIES**

The 2014 Ebola Virus Disease (EVD) outbreak in West Africa was the largest outbreak of Ebola in history, with over 28,000 cases and over 11,000 deaths<sup>11</sup>. The outbreak started in December 2013 and was first reported to the World Health Organization (WHO) in March 2014; the outbreak primarily affected the countries of Guinea, Liberia, and Sierra Leone. In September 30, 2014, the Centers for Disease Control and Prevention (CDC) confirmed the first imported case of Ebola in the United States in a man who traveled from Liberia and was hospitalized in Dallas, Texas<sup>12</sup>. Subsequently, two healthcare workers caring for that patient in Dallas, Texas were diagnosed with Ebola. Beginning in October 2014, because of increased concerns related to Ebola-imported cases to the U.S., CDC required daily monitoring for travelers returning from Ebola-affected countries<sup>13</sup>. The SFDPH conducted monitoring according to guidance from CDC and from the California Department of Public Health (CDPH). SFDPH staff interviewed returning travelers to assess their risk for developing Ebola and monitored travelers for symptoms via phone and/or video conference on a daily basis for up to 21 days. Monitoring ended in January 2016 once the WHO declared all three Ebola-affected countries (Guinea, Liberia and Sierra Leone) free of EVD<sup>14</sup>. SFDPH conducted Ebola monitoring for 112 instances of travel (several travelers made multiple trips). No cases of Ebola were identified in San Francisco or California overall during the outbreak; four cases in total were diagnosed in the U.S.<sup>12</sup>.

## **ENTEROVIRUS-D68**



Enteroviruses are ubiquitous viruses that can cause respiratory and gastrointestinal illnesses, rash and neurologic illnesses. Enteroviruses are generally transmitted from person to person via direct contact with virus shed in respiratory secretions and stool. While most infections cause mild or no symptoms, some can be severe. There are more than 100 types that cause approximately 10-15 million infections in the United States each year. Enteroviruses typically occur in the summer and fall.

Since the original isolation of enterovirus-D68 (EV-D68) in 1962, it has rarely been reported in the USA. In summer and fall 2014, the United States experienced a nationwide outbreak of EV-D68, mainly among children. EV-D68 infection was associated with severe respiratory illness, including difficulty breathing, hypoxemia, and wheezing. In California, CDPH requested that local health departments submit samples from all rhinovirus/enterovirus positive specimens from hospitalized children less than 18 years of age or from clusters of cases of any age to CDPH for further typing. From mid-August 2014 to January 15, 2015, 1,153 people in 49 states and the District of Columbia were identified with respiratory illness caused by EV-D68; EV-D68 was detected in specimens from 14 patients who died in the U.S. in 2014<sup>15</sup>. Almost all of the confirmed cases were among children, many whom had asthma or a history of wheezing. Six cases were reported in San Francisco residents between September 2014 to December 2014, and all six were children; none were fatal. It is likely that many thousands of mild EV-D68 infections occurred across the United States in people who did not seek medical treatment and/or get tested.

## LYME DISEASE

Since 1989, Lyme Disease (LD) has been a clinician-reported disease, and in June 2005, laboratories became legally required to report cases of LD to SFDPH. Interpretation of laboratory testing for LD has been and continues to be a challenge, because some commercial labs use assays where the accuracy and usefulness has not been adequately established<sup>16</sup>. In 2014, three cases of LD were reported (rate=0.4 per 100,000). Exposure information for all three cases was incomplete; only one of the three cases had available information regarding location of potential tick exposure and reported travel to a LD endemic area outside California.

## OUTBREAKS


In 2014, CDCU identified and investigated a total of 23 communicable disease outbreaks, which is fewer than the 36 outbreaks identified and investigated in 2013. It is unclear what factors contribute to the fluctuation in the number of outbreaks identified and reported, but this decrease could be a result of changes in reporting practices or a true change in the number of outbreaks.

- Etiology: Fifteen of the 23 (65%) outbreaks involved gastrointestinal illness (with two suspected to be foodborne) and five (22%) involved respiratory illness.
  - Gastrointestinal outbreaks: Four (17%) of the 23 outbreaks were caused by *Shigella sonnei* (including a large city-wide outbreak and a sub-outbreak within the city-wide outbreak; all confirmed) and four (17%) were caused by norovirus (two confirmed, two suspected). One (4%) outbreak was associated with both norovirus and *C. difficile*, but the most likely etiologic agent was norovirus.



- Respiratory outbreaks: Two (9%) of the 23 outbreaks were caused by influenza (both influenza A; both confirmed), two (9%) by *Bordetella pertussis* (both confirmed), and one (4%) by Rhinovirus/enterovirus (confirmed).
  - CDCU also provided consultation and follow-up for one (4%) confirmed outbreak of scabies (*Sarcoptes scabiei*).
- Setting: Eleven (48%) of the 23 outbreaks were associated with a long-term care facility, a skilled nursing facility, or elderly care; seven (30%) were associated with childcare, daycare, preschool or schools; two (9%) were associated with a restaurant; one (4%) was associated with a health care setting, and two (9%) were associated with other types of settings.

**Figure 3. Number and percent of reported outbreaks, 2014, San Francisco**



## PERTUSSIS

Pertussis is endemic in the U.S. with epidemic cycles every three to five years. In 2014, there was a cyclic increase in cases in California. Seventy-nine cases were reported among San Francisco residents; no deaths occurred. The incidence of pertussis in 2014 (9.4 cases per 100,000 residents, 95% CI: 7.4-11.7) was significantly higher than the incidence in 2013 (5.4 cases per 100,000 residents, 95% CI: 3.9-7.2).

Rates of pertussis have been increasing in the last 30-40 years. Reasons for this increase are unknown, but potential contributors include increased recognition and diagnosis, increased access to laboratory tests, introduction of new laboratory tests such as nucleic acid amplification tests, and increased surveillance and reporting. The increase may also be due to a true increase in incidence, possibly due to less durable immunity following vaccination with the acellular pertussis vaccine that was introduced in place of whole-cell pertussis vaccine in the 1990s.<sup>17</sup>

In 2014, rates of pertussis among San Francisco residents were highest among those under 15 years of age, with the highest rate among children aged 5-14 years (63.2 cases per 100,000 residents, 95% CI: 44.7-86.8). Since 2009, the incidence of pertussis among children aged 5-14 years has been increasing.

People of all ages can get pertussis, though death and serious complications are most likely in young infants. In October 2012, the Advisory Committee on Immunization Practices (ACIP) recommended pertussis immunization during every pregnancy to help prevent morbidity and mortality in infants<sup>18</sup>. In 2014, the case definition for pertussis was changed to better capture the burden of disease in infants who do not meet the traditional clinical case definition.

## RABIES

Six rabid bats were detected in San Francisco in 2014. Bats present a risk of rabies exposure to humans and pets, especially when they are handled or enter homes where they can have contact with people or their pets<sup>19</sup>. Rabies was not detected in any animals aside from bats in 2014, and no cases of rabies have been reported in terrestrial animals (e.g. dogs, cats, skunks, raccoons, foxes, coyotes) in San Francisco for over 60 years<sup>19</sup>. The last human rabies case in San Francisco occurred in 1987, and the presumed source was a dog bite that occurred while the patient was in the Philippines.

## SALMONELLOSIS

Since 2005, rates of salmonellosis have been increasing in San Francisco, with 2013 and 2014 having the highest rates (23.4 cases per 100,000 residents, 95% CI: 20.2-26.9 in 2013 and 21.4 cases per 100,000 residents, 95% CI: 18.4-24.8 in 2014). In 2014, 7 of the 180 cases (3.9%) reported in Table 1 were suspect; all seven suspect salmonella cases were diagnosed by CIDT alone. In previous SFDPH annual communicable disease reports, only confirmed and probable cases were included.

The increase in rates starting in 2013 is partly due to a prolonged multistate outbreak of *Salmonella* Heidelberg associated with chicken from three specific processing plants<sup>20</sup>; however, the increase is not completely attributable to the outbreak since serotypes other than Heidelberg also contributed to the increase. Other Bay Area counties also saw increases (see Figure 4).




**Figure 4. Annual incidence per 100,000 population of salmonellosis, non-typhoidal in San Francisco Bay Area Counties\*, 2012-2014**

| County        | 2012 Rate | 2013 Rate | 2014 Rate |
|---------------|-----------|-----------|-----------|
| Alameda       | 14.5      | 15.7      | 17.5      |
| Contra Costa  | 11.8      | 12.8      | 14.7      |
| Marin         | 11.0      | 14.4      | 23.3      |
| Napa          | 19.4      | 16.4      | 19.8      |
| San Francisco | 14.5      | 23.4      | 21.4      |
| San Mateo     | 19.0      | 22.5      | 18.7      |
| Santa Clara   | 15.2      | 19.2      | 19.6      |
| Solano        | 11.2      | 13.0      | 12.8      |
| Sonoma        | 13.1      | 13.2      | 12.1      |

\*Rates for Alameda County, Contra Costa County, Marin County, Napa County, San Mateo County, Santa Clara County, Solano County, and Sonoma County from California Department of Public Health Report, *Yearly Summary Reports of Selected General Communicable Diseases in California*<sup>9</sup>.

Rates of salmonellosis in 2014 were highest among those under age one year (191.9 per 100,000 residents, 95% CI: 111.8-307.3) and among 1-4 year olds (124.9 per 100,000 residents, 95% CI: 90.0-168.8), which is consistent with data from previous years (see Figure 5).





The most frequently reported *Salmonella* serotypes in 2014, which together accounted for 65.3% of the 180 cases with serotype information, were as follows: *S. Enteritidis* (18.2%), *S. Infantis* (14.7%), *S. Adelaide* (8.2%), *S. I 4,5,12:i:-* (7.0%), *S. Typhimurium* (5.3%), *S. Heidelberg* (4.7%), *S. Muenchen* (3.5%), and *S. Saint-Paul* (3.5%). The proportion of *S. Enteritidis* cases in 2014 (18.2%) is slightly higher than in 2013 (15.9%) but slightly lower than in 2012 (20.0%).

### SHIGA TOXIN-PRODUCING *ESCHIRICHIA COLI* and HEMOLYTIC UREMIC SYNDROME

Public health surveillance and reporting requirements for *Escherichia coli* have changed over time as laboratory testing methods and understanding of pathogenesis have evolved. *E. coli* O157:H7 is one of many Shiga toxin-producing *E. coli* serotypes that cause clinically and epidemiologically significant disease, including Hemolytic Uremic Syndrome (HUS). Until 2006, only *E. coli* O157:H7 and/or HUS were reportable. Since October 2006, Shiga toxin-producing *E. coli* (STEC), which encompasses *E. coli* O157:H7 and other serotypes, and Shiga toxin in feces have been reportable.

From 2007 to 2014, 122 cases of STEC were reported among San Francisco residents. The number of cases doubled from 2012 (N=12) to 2013 (N=26), primarily due to two *E. coli* O157 outbreaks: an outbreak associated with a San Francisco restaurant and a multijurisdictional outbreak associated with pre-packaged salads<sup>21</sup>. In 2014, case counts for STEC remained high with 25 cases reported (3.0 cases per 100,000 residents), and the number of Shiga toxin in feces cases increased from one in 2013 to seven in 2014; no cases of HUS were reported in 2014. This recent increase in STEC cases is consistent





with statewide trends<sup>9</sup>. The increase is hypothesized to be due to increased detection of non-O157 Shiga toxin-producing *E. coli*, increased use of Shiga toxin testing by clinical laboratories, and an increased number of specimens forwarded to a public health laboratory for culture and identification<sup>22</sup>. In 2014, clinical laboratories were required to submit Shiga toxin-positive fecal broths, and Shiga toxin-producing *Escherichia coli* (STEC) O157 and non-O157 isolates to the local public health laboratory or the State Public Health Laboratory.

## SHIGELLOSIS

Of the 269 shigellosis cases reported in 2014, five (1.9%) were classified as suspect. All five suspect cases in 2014 were diagnosed by CIDT. In previous SFDPH annual communicable disease reports, only confirmed and probable cases were included.

The rates of shigellosis in San Francisco are higher compared to other California jurisdictions<sup>2</sup> and have been increasing since 2008, with a significant increase from 2013 (14.3 cases per 100,000 residents) to 2014 (31.8 cases per 100,000 residents). The high incidence of shigellosis in San Francisco is partly attributable to sexual transmission among MSM<sup>3</sup>. The increase in 2014 is attributed to several outbreaks, including a citywide outbreak of ciprofloxacin-resistant shigellosis that disproportionately affected homeless and marginally housed individuals in San Francisco. A greater proportion of black San Francisco residents were affected in 2014 than in other years. While not statistically significant, in 2014, the incidence of shigellosis among black San Francisco residents (63.2 per 100,000 residents, 95% CI: 43.5-88.8) was higher than the shigellosis incidence of white San Francisco residents (41.6 per 100,000 residents, 95% CI: 35.1-48.8); however, this is a change from 2013 when the incidence of shigellosis among black San Francisco residents (n=1, 1.9 per 100,000 residents, 95% CI: 0.0-10.7) was significantly lower than for white San Francisco residents (20.1 per 100,000 residents, 95% CI: 15.7-25.5).

From November 1, 2014 to April 30, 2015, San Francisco experienced a city-wide outbreak of ciprofloxacin-resistant shigellosis that disproportionately affected homeless and marginally housed individuals. The outbreak was later linked to a nationwide cluster of ciprofloxacin-resistant *Shigella*. The nationwide cluster was identified based on a finding of closely related Pulsed-Field Gel Electrophoresis (PFGE) patterns in *Shigella* isolates<sup>23</sup>.

A total of 247 cases of *S. sonnei* or untyped *Shigella* with ciprofloxacin-resistance or unknown antimicrobial susceptibility were reported with specimen collection dates from November 2014 to April 2015. Only individuals with residence in or travel to San Francisco during the exposure period and no recent international travel were included as part of the outbreak. The average age of patients was 44 years, with a range of one year to 88 years. One hundred sixty-nine (68%) were male, and 123 (50%) were white. Eighty-three patients (34%) were hospitalized. Sixty-eight cases (28%) were homeless and 31 cases (13%) resided in single room occupancy (SRO) hotels. Although homeless and marginally housed individuals were not the majority of cases, they were disproportionately impacted by the outbreak.

Investigation and control activities in response to the outbreak included dissemination of a health advisory and press release, interviewing and providing health education to cases, and distribution of educational materials and hand sanitizer towelettes to agencies and organizations that serve the



homeless. SFPDPH's Environmental Health also conducted inspections and recommended prevention and control measures to SRO hotels and communal food facilities for the homeless. Despite extensive investigation, no point source or common exposure such as shelters, soup kitchens, or restaurants was identified.

## WEST NILE DISEASE AND ASYMPTOMATIC INFECTION

Since West Nile Virus (WNV) disease became reportable in June 2005, seven cases have been reported, including one in 2013. Of those seven cases, four had known travel outside San Francisco; one case was related to an organ transplant; and two cases had no known travel history and were likely exposed in San Francisco. No cases of West Nile disease were reported in 2014.

Asymptomatic infection with WNV, which is generally identified in blood donors, is also reportable to CDPH. Blood donors who test positive for WNV may not necessarily be ill, nor will they initially have positive laboratory test results. The first case of West Nile Virus infection in an asymptomatic blood donor in San Francisco was reported in 2014.

- 
1. Title 17 (Public Health), California Code of Regulations. Available from: <http://ccr.oal.ca.gov>
  2. California Confidential Morbidity Report Form. Available from: <http://www.sfcddcp.org>
  3. State of California, Department of Finance, *State and County Population Projections by Race/Ethnicity, Sex, and Age 2010-2060*. Sacramento, California, 2014 December. Available from: <http://www.dof.ca.gov/>
  4. Demographic Research Unit. *Suggested Allocations of the Multirace Category for Use with Population Projections by Race/Ethnicity for California and Its Counties 2000-2050*. Sacramento, California: California Department of Finance. 2004 Jun.
  5. National Center for Health Statistics. *Deaths: Final Data for 2002*. Hyattsville, MD: U.S. Department of Health and Human Services; 2004 Oct. 12; 53(5):109-11. Available from: [http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53\\_05acc.pdf](http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_05acc.pdf)
  6. Daly L. *Simple SAS macros for the calculation of exact binomial and Poisson confidence limits*. *Comput Biol Med.* 1992; 22(5): 351-61.
  7. Fletcher, SM et al. *Enteric Protozoa in the Developed World: A Public Health Perspective*. *Clinical Microbiology Reviews.* 2012; 25(3): 420-449.
  8. California Department of Public Health. *Yearly Summary of Selected General Communicable Diseases in California, 2001-2010*. Available from: <https://www.cdph.ca.gov/data/statistics/Documents/YearlySummaryReportsofSelectedGeneralCommDiseaseinCA2001-2010.pdf>



9. California Department of Public Health. *Yearly Summary of Selected General Communicable Diseases in California, 2011-2015*. Available from: <http://www.cdph.ca.gov/data/statistics/Documents/YearlySummaryReportsofSelectedGeneralCommDiseasesinCA2011-2015.pdf>
10. Marder EP, Cieslak PR, Cronquist AB, Dunn J, Lathrop S, Rabatsky-Ehr T, Ryan P, Smith K, Tobin-D'Angelo M, Vugia DJ, Zansky S, Holt KG, Wolpert BJ, Lynch M, Tauxe R, Geissler AL. *Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food and the Effect of Increasing Use of Culture-Independent Diagnostic Tests on Surveillance - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2013-2016*. *MMWR*. 2017 Apr 21; 66(15):397-403.
11. Centers for Disease Control and Prevention. *2014-2016 Ebola Outbreak in West Africa*. Available from: <https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/>
12. Centers for Disease Control and Prevention. *Cases of Ebola Diagnosed in the United States*. Available from: <http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/united-states-imported-case.html>
13. Centers for Disease Control and Prevention. *Notes on the Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure*. Available from: <http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html>
14. California Department of Public Health. *CDPH Concludes Ebola Monitoring Program for Travelers Returning from West African Countries*. Available from: <http://www.cdph.ca.gov/Pages/NR16-003.aspx>
15. Centers for Disease Control and Prevention. <https://www.cdc.gov/non-polio-enterovirus/about/EV-D68.html>
16. Centers for Disease Control and Prevention. *Notice to Readers: Caution regarding testing for Lyme Disease*. *MMWR*. 2005; 54(5): 125.
17. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. *Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers*. *Pediatrics*. 2013 June; 131(6). Available from: <http://pediatrics.aappublications.org/content/131/6/e1716>
18. Centers for Disease Control and Prevention. *Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012*. *MMWR*. 2013; 62(07):131-135. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm>
19. Communicable Disease Control and Prevention Section. *Community Health & Safety Bulletin*. [Internet] San Francisco, California: San Francisco Department of Public Health. 2004 June/July; 1(1):1-3. Available from <http://www.sfcddcp.org/publications.html>
20. California Department of Public Health. *Investigation of a Salmonella Heidelberg Outbreak in 2013 and 2014 associated with Foster Farms chicken*. 2014 June. Available from: <https://www.cdph.ca.gov/pubsforms/Documents/fdbEIRFF2014.pdf>
21. California Department of Public Health. *Epidemiologic Summary of Shiga toxin-producing Escherichia coli (STEC) infections and Hemolytic Uremic Syndrome (HUS) in California, 2009-2012*. Available from: <https://www.cdph.ca.gov/programs/sss/Documents/STECandHUSEpiSummary2009-2012.pdf>



22. California Department of Public Health. *Environmental investigation of Escherichia coli O157:H7 outbreak in October 2013 associated with pre-packaged salads*. 2014 July. Available from: <https://www.cdph.ca.gov/HealthInfo/Documents/fdbEIRRB2014.pdf>
23. Bowen, A et al. *Importation and Domestic Transmission of Shigella sonnei Resistant to Ciprofloxacin - United States, May 2014–February 2015*. MMWR. 2015 April 3; 64(12):318-320.



| Disease                                      | N   | Rate  |
|--|-----|-------|
| Amebiasis                                    | 55  | 6.5   |
| Anaplasmosis/Ehrlichiosis                    | 1   | 0.1 * |
| Anthrax                                      | 0   | 0.0   |
| Babesiosis                                   | 0   | 0.0   |
| Botulism, Foodborne                          | 0   | 0.0   |
| Botulism, Infant (1)                         | 0   | 0.0   |
| Botulism, Unspecified                        | 0   | 0.0   |
| Botulism, Wound                              | 0   | 0.0   |
| Brucellosis                                  | 0   | 0.0   |
| Campylobacteriosis (2)                       | 405 | 48.2  |
| Chickenpox, Severe (Death or Hosp)           | 1   | 0.1 * |
| Chikungunya                                  | 2   | 0.2 * |
| Cholera                                      | 0   | 0.0   |
| Ciguatera Fish Poisoning                     | 0   | 0.0   |
| Coccidioidomycosis                           | 5   | 0.6 * |
| Creutzfeldt-Jakob Dis. or Other TSE (3)      | 4   | 0.5 * |
| Cryptosporidiosis                            | 16  | 1.9 * |
| Cysticercosis or Taeniasis                   | 0   | 0.0   |
| Dengue                                       | 8   | 1.0 * |
| Diphtheria                                   | 0   | 0.0   |
| Domoic Acid Poisoning                        | 0   | 0.0   |
| Encephalitis, Arboviral                      | 0   | 0.0   |
| Encephalitis, Bacterial                      | 0   | 0.0   |
| Encephalitis, Fungal                         | 0   | 0.0   |
| Encephalitis, Other Viral                    | 1   | 0.1 * |
| Encephalitis, Parasitic                      | 0   | 0.0   |
| Encephalitis, Unspecified                    | 1   | 0.1 * |
| Encephalitis, Total                          | 2   | 0.2 * |
| Giardiasis                                   | 164 | 19.5  |
| <i>Haemophilus influenzae</i> , Invasive (4) | 2   | 1.9 * |
| Hantavirus Infection                         | 0   | 0.0   |
| Hemolytic Uremic Syndrome (5)                | 0   | 0.0   |
| Hepatitis A                                  | 6   | 0.7 * |
| Hepatitis B, Acute (6)                       | 2   | 0.2 * |
| Hepatitis C, Acute                           | 0   | 0.0   |
| Hepatitis Delta                              | 0   | 0.0   |
| Hepatitis E                                  | 1   | 0.1 * |
| Influenza, Deaths, 0-64 years of age         | 1   | 0.1 * |
| Legionellosis                                | 2   | 0.2 * |
| Leprosy                                      | 0   | 0.0   |
| Leptospirosis                                | 0   | 0.0   |
| Listeriosis                                  | 8   | 1.0 * |
| Lyme Disease                                 | 3   | 0.4 * |
| Malaria                                      | 8   | 1.0 * |
| Measles                                      | 0   | 0.0   |

| Disease                                   | N   | Rate  |
|---|-----|-------|
| Meningitis, Bacterial                     | 6   | 0.7 * |
| Meningitis, Fungal                        | 2   | 0.2 * |
| Meningitis, Parasitic                     | 0   | 0.0   |
| Meningitis, Unspecified                   | 0   | 0.0   |
| Meningitis, Viral                         | 3   | 0.4 * |
| Meningitis, Total                         | 11  | 1.3 * |
| Meningococcal Infection                   | 2   | 0.2 * |
| Mumps                                     | 1   | 0.1 * |
| Outbreaks, Foodborne                      | 2   | N/A   |
| Outbreaks, Non-Foodborne                  | 21  | N/A   |
| Paralytic Shellfish Poisoning             | 0   | 0.0   |
| Pertussis                                 | 79  | 9.4   |
| Plague                                    | 0   | 0.0   |
| Poliovirus Infection                      | 0   | 0.0   |
| Psittacosis                               | 0   | 0.0   |
| Q Fever                                   | 0   | 0.0   |
| Rabies, Animal                            | 6   | N/A   |
| Rabies, Human                             | 0   | 0.0   |
| Relapsing Fever                           | 0   | 0.0   |
| Rickettsial Diseases (not RMSF or Typhus) | 0   | 0.0   |
| Rocky Mountain Spotted Fever              | 1   | 0.1 * |
| Rubella                                   | 0   | 0.0   |
| Rubella, Congenital                       | 0   | 0.0   |
| STEC including E. coli O157               | 25  | 3.0   |
| Salmonellosis (2)                         | 180 | 21.4  |
| Scombroid Fish Poisoning                  | 1   | 0.1 * |
| Severe Acute Respiratory Syndrome         | 0   | 0.0   |
| Severe Staph. aureus infection            | 0   | 0.0   |
| Shiga toxin (detected in feces)           | 7   | 0.8 * |
| Shigellosis, Group B: <i>S. flexneri</i>  | 65  | 7.7   |
| Shigellosis, Group D: <i>S. sonnei</i>    | 190 | 22.6  |
| Shigellosis, Other Group (2)              | 12  | 1.4 * |
| Shigellosis, Total (2)                    | 267 | 31.8  |
| Smallpox                                  | 0   | 0.0   |
| Streptococcal Infection                   | 0   | 0.0   |
| Tetanus                                   | 0   | 0.0   |
| Toxic Shock Syndrome                      | 0   | 0.0   |
| Trichinosis                               | 0   | 0.0   |
| Tularemia                                 | 0   | 0.0   |
| Typhoid Carrier                           | 0   | 0.0   |
| Typhoid Fever, Acute                      | 1   | 0.1 * |
| Typhus Fever                              | 0   | 0.0   |
| Vibriosis, Non-Cholera                    | 21  | 2.5   |
| Viral Hemorrhagic Fever                   | 0   | 0.0   |
| West Nile Asymptomatic blood donor        | 1   | 0.1 * |
| West Nile Disease                         | 0   | 0.0   |
| West Nile Infections, Total (7)           | 1   | 0.1 * |
| Yellow Fever                              | 0   | 0.0   |
| Yersiniosis                               | 4   | 0.5 * |

(1) Rate among residents age <1 yr. (2) Includes suspect cases (3) TSE = transmissible spongiform encephalopathies (e.g., vCJD, kuru). (4) Reportable in <15 yrs; rate for residents aged <15 yrs. (5) Includes HUS only and E. coli STEC cases with HUS (6) Includes perinatal cases. (7) Includes both West Nile Disease & asymptomatic infections  
 \*=Unstable Rates (where n<20) should not be compared statistically. See report appendix for disease reporting changes and selected disease definitions.  
 Source: SFDPH Communicable Disease Control Unit. Data shown by year cases were reported to SFDPH. Rates are cases per 100,000 population. Population estimates from the California Department of Finance.

**TABLE 2: FREQUENCY AND UNADJUSTED RATES FOR SIX SELECTED DISEASES BY AGE, SAN FRANCISCO, 2014**

| Year | Amebiasis |    |        |       |         | Campylobacteriosis |      |         |        |         | Giardiasis |        |        |       |      |
|------|-----------|----|--------|-------|---------|--------------------|------|---------|--------|---------|------------|--------|--------|-------|------|
|      | Age       | N  | Rate   | 95%CI |         | Age                | N    | Rate    | 95% CI |         | Age        | N      | Rate   | 95%CI |      |
| 2014 | 0-14 yrs  | 0  | 0.0 *  |       |         | <1 yr              | 9    | 101.6 * | 46.5   | 192.9   | <1 yr      | 0      | 0.0 *  |       |      |
|      | 15-24 yrs | 1  | 1.3 *  | 0.0   | 7.4     | 1-4 yrs            | 28   | 83.3    | 55.3   | 120.3   | 1-4 yrs    | 5      | 14.9 * | 4.8   | 34.7 |
|      | 25-34 yrs | 15 | 8.8 *  | 4.9   | 14.5    | 5-14 yrs           | 35   | 58.2    | 40.6   | 81.0    | 5-14 yrs   | 5      | 8.3 *  | 2.7   | 19.4 |
|      | 35-44 yrs | 11 | 7.5 *  | 3.7   | 13.3    | 15-24 yrs          | 31   | 41.3    | 28.1   | 58.6    | 15-24 yrs  | 4      | 5.3 *  | 1.5   | 13.6 |
|      | 45-54 yrs | 19 | 16.6 * | 10.0  | 25.9    | 25-34 yrs          | 105  | 61.4    | 50.2   | 74.4    | 25-34 yrs  | 35     | 20.5   | 14.3  | 28.5 |
|      | 55-64 yrs | 7  | 6.8 *  | 2.7   | 13.9    | 35-44 yrs          | 62   | 42.0    | 32.2   | 53.9    | 35-44 yrs  | 43     | 29.2   | 21.1  | 39.3 |
|      | 65+ yrs   | 2  | 1.6 *  | 0.2   | 5.7     | 45-54 yrs          | 43   | 37.6    | 27.2   | 50.6    | 45-54 yrs  | 36     | 31.4   | 22.0  | 43.5 |
|      | Total     | 55 | 6.5    | 4.9   | 8.5     | 55-64 yrs          | 41   | 39.6    | 28.4   | 53.7    | 55-64 yrs  | 21     | 20.3   | 12.6  | 31.0 |
|      |           |    |        |       | 65+ yrs | 51                 | 40.4 | 30.1    | 53.1   | 65+ yrs | 15         | 11.9 * | 6.6    | 19.6  |      |
|      |           |    |        |       | Total   | 405                | 48.2 | 43.6    | 53.1   | Total   | 164        | 19.5   | 16.6   | 22.7  |      |

| Year | Pertussis |    |        |        |      | Salmonellosis |     |         |        |       |
|------|-----------|----|--------|--------|------|---------------|-----|---------|--------|-------|
|      | Age       | N  | Rate   | 95% CI |      | Age           | N   | Rate    | 95% CI |       |
| 2014 | <1 yr     | 2  | 22.6 * | 2.7    | 81.6 | <1 yr         | 17  | 191.9 * | 111.8  | 307.3 |
|      | 1-4 yrs   | 6  | 17.8 * | 6.5    | 38.8 | 1-4 yrs       | 42  | 124.9   | 90.0   | 168.8 |
|      | 5-14 yrs  | 38 | 63.2   | 44.7   | 86.8 | 5-14 yrs      | 12  | 20.0 *  | 10.3   | 34.9  |
|      | 15-24 yrs | 20 | 26.6   | 16.3   | 41.1 | 15-24 yrs     | 23  | 30.6    | 19.4   | 46.0  |
|      | 25-34 yrs | 1  | 0.6 *  | 0.0    | 3.3  | 25-34 yrs     | 29  | 17.0    | 11.4   | 24.4  |
|      | 35-44 yrs | 4  | 2.7 *  | 0.7    | 6.9  | 35-44 yrs     | 12  | 8.1 *   | 4.2    | 14.2  |
|      | 45-54 yrs | 3  | 2.6 *  | 0.5    | 7.7  | 45-54 yrs     | 12  | 10.5 *  | 5.4    | 18.3  |
|      | 55-64 yrs | 3  | 2.9 *  | 0.6    | 8.5  | 55-64 yrs     | 13  | 12.6 *  | 6.7    | 21.5  |
|      | 65+ yrs   | 2  | 1.6 *  | 0.2    | 5.7  | 65+ yrs       | 20  | 15.8    | 9.7    | 24.4  |
|      | Total     | 79 | 9.4    | 7.4    | 11.7 | Total         | 180 | 21.4    | 18.4   | 24.8  |

| Year | Shigellosis (Total) |     |        |       |      | Shigellosis (flexneri) |    |        |       |      | Shigellosis (sonnei) |     |        |        |      |
|------|---------------------|-----|--------|-------|------|------------------------|----|--------|-------|------|----------------------|-----|--------|--------|------|
|      | Age                 | N   | Rate   | 95%CI |      | Age                    | N  | Rate   | 95%CI |      | Age                  | N   | Rate   | 95% CI |      |
| 2014 | <1 yr               | 0   | 0.0 *  |       |      | 0-24 yrs               | 0  | 0.0 *  |       |      | <1 yr                | 0   | 0.0 *  |        |      |
|      | 1-4 yrs             | 6   | 17.8 * | 6.5   | 38.8 | 25-34 yrs              | 12 | 7.0 *  | 3.6   | 12.3 | 1-4 yrs              | 6   | 17.8 * | 6.5    | 38.8 |
|      | 5-14 yrs            | 6   | 10.0 * | 3.7   | 21.7 | 35-44 yrs              | 16 | 10.9 * | 6.2   | 17.6 | 5-14 yrs             | 5   | 8.3 *  | 2.7    | 19.4 |
|      | 15-24 yrs           | 12  | 16.0 * | 8.3   | 27.9 | 45-54 yrs              | 20 | 17.5   | 10.7  | 27.0 | 15-24 yrs            | 12  | 16.0 * | 8.3    | 27.9 |
|      | 25-34 yrs           | 45  | 26.3   | 19.2  | 35.2 | 55-64 yrs              | 12 | 11.6 * | 6.0   | 20.3 | 25-34 yrs            | 30  | 17.6   | 11.8   | 25.1 |
|      | 35-44 yrs           | 60  | 40.7   | 31.1  | 52.4 | 65+ yrs                | 5  | 4.0 *  | 1.3   | 9.2  | 35-44 yrs            | 41  | 27.8   | 20.0   | 37.7 |
|      | 45-54 yrs           | 81  | 70.7   | 56.2  | 87.9 | Total                  | 65 | 7.7    | 6.0   | 9.9  | 45-54 yrs            | 57  | 49.8   | 37.7   | 64.5 |
|      | 55-64 yrs           | 45  | 43.5   | 31.7  | 58.2 |                        |    |        |       |      | 55-64 yrs            | 32  | 30.9   | 21.1   | 43.6 |
|      | 65+ yrs             | 12  | 9.5 *  | 4.9   | 16.6 |                        |    |        |       |      | 65+ yrs              | 7   | 5.5 *  | 2.2    | 11.4 |
|      | Total               | 267 | 31.8   | 28.1  | 35.8 |                        |    |        |       |      | Total                | 190 | 22.6   | 19.5   | 26.1 |

\*=Unstable Rate (n<20). Unstable rates should not be compared statistically. 95%CI=Confidence Intervals; 95% Exact Confidence Intervals not displayed for counts of zero. Cases with missing age are represented in total column counts only. Thus, the sum of individual age groups for these diseases does not match the total column count shown.

Source: SFPDPH Communicable Disease Control Unit. Data shown by year cases reported to SFPDPH. Rates are cases per 100,000 population. Population estimates obtained from the California Department of Finance. This report uses 2014 estimates.

**TABLE 3: FREQUENCY AND UNADJUSTED RATES FOR SIX SELECTED DISEASES BY SEX, SAN FRANCISCO, 2014**

| Year | Sex    | N  | Amebiasis |        |      | Sex    | N   | Campylobacteriosis |        |      | Sex    | N   | Giardiasis |        |      |
|------|--------|----|-----------|--------|------|--------|-----|--------------------|--------|------|--------|-----|------------|--------|------|
|      |        |    | Rate      | 95% CI |      |        |     | Rate               | 95% CI |      |        |     | Rate       | 95% CI |      |
| 2014 | Male   | 54 | 12.7      | 9.5    | 16.5 | Male   | 230 | 54.0               | 47.2   | 61.4 | Male   | 126 | 29.6       | 24.6   | 35.2 |
|      | Female | 1  | 0.2*      | 0.0    | 1.3  | Female | 175 | 42.3               | 36.2   | 49.0 | Female | 36  | 8.7        | 6.1    | 12.0 |
|      | Unk    | 0  |           |        |      | Unk    | 0   |                    |        |      | Unk    | 2   |            |        |      |
|      | Total  | 55 | 6.5       | 4.9    | 8.5  | Total  | 405 | 48.2               | 43.6   | 53.1 | Total  | 164 | 19.5       | 16.6   | 22.7 |

| Year | Sex    | N  | Pertussis |        |      | Sex    | N   | Salmonellosis |        |      |
|------|--------|----|-----------|--------|------|--------|-----|---------------|--------|------|
|      |        |    | Rate      | 95% CI |      |        |     | Rate          | 95% CI |      |
| 2014 | Male   | 43 | 10.1      | 7.3    | 13.6 | Male   | 95  | 22.3          | 18.0   | 27.2 |
|      | Female | 36 | 8.7       | 6.1    | 12.0 | Female | 85  | 20.5          | 16.4   | 25.4 |
|      | Unk    | 0  |           |        |      | Unk    | 0   |               |        |      |
|      | Total  | 79 | 9.4       | 7.4    | 11.7 | Total  | 180 | 21.4          | 18.4   | 24.8 |

| Year | Sex    | N   | Shigellosis (Total) |        |      | Sex    | N  | Shigellosis (flexneri) |        |      | Sex    | N   | Shigellosis (sonnei) |        |      |
|------|--------|-----|---------------------|--------|------|--------|----|------------------------|--------|------|--------|-----|----------------------|--------|------|
|      |        |     | Rate                | 95% CI |      |        |    | Rate                   | 95% CI |      |        |     | Rate                 | 95% CI |      |
| 2014 | Male   | 210 | 49.3                | 42.8   | 56.4 | Male   | 61 | 14.3                   | 10.9   | 18.4 | Male   | 139 | 32.6                 | 27.4   | 38.5 |
|      | Female | 57  | 13.8                | 10.4   | 17.8 | Female | 4  | 1.0*                   | 0.3    | 2.5  | Female | 51  | 12.3                 | 9.2    | 16.2 |
|      | Unk    | 0   |                     |        |      | Unk    | 0  |                        |        |      | Unk    | 0   |                      |        |      |
|      | Total  | 267 | 31.8                | 28.1   | 35.8 | Total  | 65 | 7.7                    | 6.0    | 9.9  | Total  | 190 | 22.6                 | 19.5   | 26.1 |

Rates are cases per 100,000 population; Rates not calculated for the sex category Unknown; \*=Unstable Rate (n<20); Unstable rates should not be compared statistically. 95%CI=Confidence Intervals; 95% Exact Confidence Intervals not displayed for counts of zero.

Source: SFPDH Communicable Disease Control Unit. Data shown by year cases reported to SFPDH. Population estimates obtained from the California Department of Finance. This report uses 2014 estimates.

**TABLE 4: FREQUENCY AND UNADJUSTED RATES FOR FOUR SELECTED DISEASES BY RACE/ETHNICITY, SAN FRANCISCO, 2014**

| Year | Race/<br>Ethnicity | Amebiasis |      |        |      | Pertussis |       |        |      | Salmonellosis |      |        |      |
|------|--------------------|-----------|------|--------|------|-----------|-------|--------|------|---------------|------|--------|------|
|      |                    | N         | Rate | 95% CI |      | N         | Rate  | 95% CI |      | N             | Rate | 95% CI |      |
| 2014 | White              | 34        | 9.7  | 6.7    | 13.6 | 24        | 6.9   | 4.4    | 10.2 | 50            | 14.3 | 10.6   | 18.9 |
|      | Black              | 1         | 1.9* | 0.0    | 10.7 | 2         | 3.8*  | 0.5    | 13.8 | 5             | 9.6* | 3.1    | 22.3 |
|      | Asian/PI           | 2         | 0.7* | 0.1    | 2.4  | 6         | 2.0*  | 0.7    | 4.4  | 76            | 25.4 | 20.0   | 31.8 |
|      | Hispanic           | 10        | 7.6* | 3.6    | 13.9 | 17        | 12.9* | 7.5    | 20.6 | 27            | 20.4 | 13.5   | 29.7 |
|      | Other/Unk          | 8         |      |        |      | 30        |       |        |      | 22            |      |        |      |
|      | Total              | 55        | 6.5  | 4.9    | 8.5  | 79        | 9.4   | 7.4    | 11.7 | 180           | 21.4 | 18.4   | 24.8 |

| Year | Race/<br>Ethnicity | Shigellosis (Total) |      |        |      | Shigellosis (flexneri) |       |        |      | Shigellosis (sonnei) |      |        |      |
|------|--------------------|---------------------|------|--------|------|------------------------|-------|--------|------|----------------------|------|--------|------|
|      |                    | N                   | Rate | 95% CI |      | N                      | Rate  | 95% CI |      | N                    | Rate | 95% CI |      |
| 2014 | White              | 145                 | 41.6 | 35.1   | 48.9 | 34                     | 9.7   | 6.7    | 13.6 | 103                  | 29.5 | 24.1   | 35.8 |
|      | Black              | 33                  | 63.2 | 43.5   | 88.8 | 7                      | 13.4* | 5.4    | 27.6 | 26                   | 49.8 | 32.5   | 73.0 |
|      | Asian/PI           | 11                  | 3.7* | 1.8    | 6.6  | 1                      | 0.3*  | 0.0    | 1.9  | 10                   | 3.3* | 1.6    | 6.1  |
|      | Hispanic           | 23                  | 17.4 | 11.0   | 26.1 | 10                     | 7.6*  | 3.6    | 13.9 | 12                   | 9.1* | 4.7    | 15.9 |
|      | Other/Unk          | 55                  |      |        |      | 13                     |       |        |      | 39                   |      |        |      |
|      | Total              | 267                 | 31.8 | 28.1   | 35.8 | 65                     | 7.7   | 6.0    | 9.9  | 190                  | 22.6 | 19.5   | 26.1 |

Asian/PI = Asian or Pacific Islander ;there were no cases of these select diseases among people identified as American Indian/Alaskan Native.

Rates are cases per 100,000 population; Rates not calculated for the race/ethnicity categories Other & Unknown. \*=Unstable Rate (n<20). Unstable rates should not be compared statistically.

95%LCL=Exact Lower Confidence Limit, 95%UCL=Exact Upper Confidence Limit; 95% Exact Confidence Limits not displayed for counts of zero.

Source: SFPDPH Communicable Disease Control Unit. Data shown by year cases reported to SFPDPH. Population estimates obtained from the California Department of Finance. This report uses 2014 estimates.



TABLE 5: SAN FRANCISCO POPULATION ESTIMATES BY SEX, AGE AND RACE/ETHNICITY, 2014

| Year    | Sex    | Age            | White          | Hispanic      | Black          | Asian/PI       | Am Indian      | Total          |
|---------|--------|----------------|----------------|---------------|----------------|----------------|----------------|----------------|
| 2014    | FEMALE | <1 yr          | 1,697          | 849           | 278            | 1,423          | 94             | 4,341          |
|         |        | 1-4 yrs        | 6,382          | 3,355         | 1,089          | 5,290          | 357            | 16,473         |
|         |        | 5-14 yrs       | 8,369          | 7,409         | 2,567          | 10,654         | 584            | 29,583         |
|         |        | 15-24 yrs      | 10,670         | 7,880         | 3,400          | 15,250         | 445            | 37,645         |
|         |        | 25-34 yrs      | 41,065         | 12,327        | 3,774          | 27,743         | 821            | 85,730         |
|         |        | 35-44 yrs      | 32,227         | 10,476        | 3,207          | 22,743         | 556            | 69,209         |
|         |        | 45-54 yrs      | 18,985         | 7,115         | 3,328          | 21,764         | 388            | 51,580         |
|         |        | 55-64 yrs      | 17,444         | 5,753         | 3,432          | 23,055         | 274            | 49,958         |
|         |        | 65+ yrs        | 25,894         | 7,096         | 4,521          | 31,845         | 288            | 69,644         |
|         |        |                | <b>162,733</b> | <b>62,260</b> | <b>25,596</b>  | <b>159,767</b> | <b>3,807</b>   | <b>414,163</b> |
|         | MALE   | <1 yr          | 1,766          | 883           | 289            | 1,480          | 99             | 4,517          |
|         |        | 1-4 yrs        | 6,624          | 3,457         | 1,153          | 5,533          | 388            | 17,155         |
|         |        | 5-14 yrs       | 8,358          | 7,820         | 2,602          | 11,094         | 638            | 30,512         |
|         |        | 15-24 yrs      | 8,929          | 8,296         | 3,269          | 16,529         | 422            | 37,445         |
|         |        | 25-34 yrs      | 41,464         | 15,213        | 3,406          | 24,390         | 715            | 85,188         |
|         |        | 35-44 yrs      | 41,183         | 13,551        | 3,431          | 19,460         | 617            | 78,242         |
|         |        | 45-54 yrs      | 29,910         | 9,655         | 4,356          | 18,455         | 545            | 62,921         |
|         |        | 55-64 yrs      | 23,179         | 6,104         | 4,408          | 19,528         | 320            | 53,539         |
| 65+ yrs |        | 24,703         | 4,920          | 3,703         | 23,114         | 270            | 56,710         |                |
|         |        | <b>186,116</b> | <b>69,899</b>  | <b>26,617</b> | <b>139,583</b> | <b>4,014</b>   | <b>426,229</b> |                |
|         |        | <b>348,849</b> | <b>132,159</b> | <b>52,213</b> | <b>299,350</b> | <b>7,821</b>   | <b>840,392</b> |                |

Source: California Department of Finance, Demographic Research Unit. This report uses 2014 estimates.

Note: Am Indian=American Indian/Alaska Native; Asian/PI=Asian/Pacific Islander.

## Appendix: Notifiable Disease - Historical Changes (2004 - 2014)

The diseases required to be reported to public health and disease definitions can change over time. Changes in disease definitions can impact the numbers of cases of disease reported to the SFDPH. Documentation of changes in definitions from 2004 – 2014 are outlined below.

For documentation of changes from 1986 to 2003, please refer to The San Francisco Communicable Disease Report 1986-2003 (May 2005), accessible at: <http://sfcdcp.org/publications.html>.

| <u>Date of change</u> | <u>Disease</u>   | <u>Description</u>   |
|-----------------------|--|--|
| 2005                  | <b>Acute hepatitis B</b>   | Includes perinatal cases starting in 2005.   |
| June 2005             | <b>Lyme disease</b>  | Clinician reportable since 1989, and also became laboratory-reportable in June 2005.   |
| June 2005             | <b>Severe Acute Respiratory Syndrome (SARS)</b>  | Became reportable in June 2005.  |
| June 2005             | <b>West Nile Disease</b>   | Includes West Nile Fever, West Nile Meningitis, & West Nile Encephalitis, and became reportable in June 2005.  |
| October 2006          | <b>Non-O157:H7 Shiga toxin producing <i>Escherichia coli</i> (STEC) infections</b>         | Non-O157:H7 STEC infections became notifiable in California in October 2006.   |
| June 2007             | <b>Anisakiasis</b>   | Removed from the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Avian Influenza (H5N1)</b>  | Human infection with the influenza A H5N1 virus was added to the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Chickenpox</b>  | Previously all varicella hospitalizations and deaths (including shingles) were reportable, but as of June 2007, only chickenpox hospitalizations and deaths are reportable.  |
| June 2007             | <b>Creutzfeldt-Jakob Disease (CJD) and other Transmissible Spongiform Encephalopathies</b> | Added to the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Echinococcosis</b>  | Removed from the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Influenza Deaths, Pediatric</b>   | Deaths associated with infection with an influenza virus are reportable in patients <18 years of age and were added to the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Invasive <i>Haemophilus influenzae</i> Disease</b>                                      | Reportable only in patients <15 years of age as of June 2007. Prior to June 2007, it was reportable in patients <30 years of age.  |
| June 2007             | <b>Lymphocytic Choriomeningitis</b>  | Removed from the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Reye Syndrome</b>   | Removed from the list of notifiable diseases in California in June 2007.   |
| June 2007             | <b>Shiga toxin producing <i>Escherichia coli</i> (STEC) infections</b>                     | All <i>E. coli</i> O157 STEC (regardless of presence of H7 antigen) became notifiable in California in June 2007. Case counts and rates for STEC, <i>E. coli</i> O157:H7 and <i>E. coli</i> O157 non-H7 infections are presented together. |
| June 2007             | <b>Taeniasis</b>   | Added to the list of notifiable diseases in California in June 2007.   |



|               |   |  |
|---------------|---|--|
| February 2008 | <b>Severe <i>Staphylococcus aureus</i> infection</b>            | Severe <i>Staphylococcus aureus</i> infection in a “previously healthy person” has been a reportable condition in California since February 13, 2008. For the purposes of surveillance, a severe infection is defined as one resulting in death or admission to an intensive care unit, and a previously healthy person is defined as one who has not been hospitalized or had surgery, dialysis, or residency in a long-term care facility in the past year and did not have an indwelling catheter or percutaneous medical device at the onset of illness. A <i>S. aureus</i> infection in a person without these healthcare-associated risk factors would be considered community-associated. |
| February 2008 | <b>Smallpox</b>   | Eradicated in 1979; reportable again since 2001 for bioterror surveillance.  |
| 2009          | <b>Anaplasmosis/Ehrlichiosis</b>                                | Add Anaplasmosis to Ehrlichiosis   |
| 2009          | <b>Poliovirus infection</b>                                     | Change poliomyelitis to poliovirus infection.  |
| July 2011     | <b>Anthrax, animal</b>  | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Brucellosis, animal</b>                                      | Added to the list of notifiable diseases in California in July 2011. Excludes infections due to <i>Brucella canis</i>  |
| July 2011     | <b>Hepatitis D</b>  | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Hepatitis E</b>  | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Influenza, deaths</b>  | Added to the list of notifiable diseases in California in July 2011. Only deaths of laboratory-confirmed cases of patients ages 0-64 years.  |
| July 2011     | <b>Influenza, novel strains</b>                                 | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Rickettsial Diseases</b>                                     | Added to the list of notifiable diseases in California in July 2011. Does not include Rocky Mountain Spotted Fever or Typhus.  |
| July 2011     | <b>Tularemia, animal</b>  | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Viral Hemorrhagic Fevers, animal</b>                         | Added to the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Avian influenza (human)</b>                                  | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Colorado Tick Fever</b>                                      | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Hepatitis, Viral</b>   | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Hepatitis, other, acute</b>                                  | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Influenza (report in a person less than 18 years of age)</b> | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Kawasaki Syndrome</b>  | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Rheumatic Fever, acute</b>                                   | Removed from the list of notifiable diseases in California in July 2011.   |
| July 2011     | <b>Water-associated disease</b>                                 | Removed from the list of notifiable diseases in California in July 2011. Includes Swimmer’s Itch and Hot Tub Rash.   |
| Jan 2014      | <b>Pertussis</b>  | Includes revision to clinical signs and symptoms for infants   |



---

## Appendix: Definitions for Select Notifiable Diseases

---

|                                |   |
|--------------------------------|---|
| <b>Bacterial Meningitis</b>    | Excludes meningitis caused by <i>Neisseria meningitidis</i> , which is listed separately as Meningococcal Infections.   |
| <b>Cholera</b>                 | Is caused by <i>Vibrio cholerae</i> serogroup O1 or O139.   |
| <b>Meningococcal Infection</b> | Are <i>N. meningitidis</i> infections that result in meningitis, meningococemia or other infections.  |
| <b>Outbreaks</b>               | <p>Foodborne outbreaks are defined by 4 or more illnesses with a common food exposure. Other outbreaks of any disease, including those not reportable per CCR Title 17, are defined by an increase in cases above the expected number for a given time period. Additionally, cases may be subjectively classified as an outbreak based on common exposures or other epidemiologic information.</p> <p>In 2011, CDCU changed the way outbreak information was stored and processed; therefore, outbreak data from years before 2011 may not be comparable.</p> |
| <b>Salmonellosis</b>           | Includes the more than 2,500 recognized serotypes of <i>Salmonella</i> spp., excluding <i>S. Typhi</i> , which causes typhoid fever.  |
| <b>Streptococcal Infection</b> | Individual cases of streptococcal infection are reportable only if diagnosed in foodhandlers or dairy workers.  |
| <b>Typhoid Fever</b>           | Is caused by infection with <i>S. Typhi</i> .   |
| <b>Vibriosis</b>               | Is caused by other <i>Vibrio cholerae</i> serogroups (non-O1, non-O139) and other <i>Vibrio</i> spp., including <i>V. parahaemolyticus</i> and <i>V. vulnificus</i> .   |
| <b>Viral Hemorrhagic Fever</b> | Includes hemorrhagic fevers caused by filoviruses (e.g., Ebola, Marburg), arenaviruses (e.g., Lassa fever, Machupo), bunyaviruses (e.g., Crimean-Congo), and flaviviruses (e.g., Omsk). Yellow fever and dengue are listed separately and not included in this category.  |

